Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.

AIDS (London, England) - 17 Jul 2012

Bartlett John A, Ribaudo Heather J, Wallis Carole L, Aga Evgenia, Katzenstein David A, Stevens Wendy S, Norton Michael R, Klingman Karin L, Hosseinipour Mina C, Crump John A, Supparatpinyo Khuanchai, Badal-Faesen Sharlaa, Kallungal Beatrice A, Kumarasamy Nagalingeswaran

Abstract excerpt

OBJECTIVE: To evaluate virologic response rates of lopinavir/ritonavir (LPV/r) monotherapy as second-line antiretroviral treatment (ART) among adults in resource-limited settings (RLSs). DESIGN: An open-label pilot study of LPV/r monotherapy in participants on first-line nonnucleoside reverse transcriptase inhibitor three-drug combination ART with plasma HIV-1 RNA 1000-200 000 copies/ml. METHODS: Participants...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Emtricitabine

Share to Lopinavir

Share to Medication Adherence

Share to Organophosphonates

Share to Ritonavir

Share to Tenofovir

Source

Open in PubMed Open full text

Identifiers

PMID: 22441252
DOI: 10.1097/QAD.0b013e328353b066
PMCID: PMC3443745

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.PMID 22441252Read ↗

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority studySemantic proximity Read ↗

Drug Susceptibility and Resistance Mutations After First-Line Failure in Resource Limited SettingsSemantic proximity Read ↗

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.Semantic proximity Read ↗

Outcomes after virologic failure of first-line ART in South Africa.Semantic proximity Read ↗

HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.Semantic proximity Read ↗

Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.Semantic proximity Read ↗

Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir.Semantic proximity Read ↗

Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.Semantic proximity Read ↗

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).Semantic proximity Read ↗

Genotypic resistance profiles of HIV-2-treated patients in West Africa.Semantic proximity Read ↗

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.Semantic proximity Read ↗

Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.